Participate in a Trial

Potential new vaccine for preventing chlamydia infection

If you are aged 18 to 29 years, are in good general health and don’t currently have chlamydia, you may be eligible to participate in the trial of an investigational chlamydia vaccine.

Select a location

Sunshine Coast and Noosa

Learn more or register for a clinical trial currently underway at our Noosa, Sippy Downs and Birtinya clinics

Moreton Bay

Learn more or register for a clinical trial currently underway at our Morayfield clinic

Brisbane

Learn more or register for a clinical trial currently underway at our South Bank clinic

Sunshine Coast Haematology and Oncology Clinic

Specialist cancer trials

Learn more or register for a specialist cancer clinical trial currently underway at our Buderim clinic, run through the Sunshine Coast Haematology and Oncology Clinic

Frequently asked questions

Got a question about clinical trials? Get answers here.

Share your experience

We’re committed to a culture of continuous improvement. Feedback from our participants is invaluable to us and helps us create better clinical trial experiences for future trials. Click to share your thoughts.

Completed studies

When available, the results of studies completed by UniSC Clinical Trials are listed below.

Protocol Number	Protocol	Results Available?
205715	A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma	Media Release Results Available
200812	A Phase III, 4-week, randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI), 'open' triple therapy (FF/VI + UMEC) and dual therapy (FF/VI) in subjects with chronic obstructive pulmonary disease (COPD)	Results Available
RTB-101-204	A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Symptomatic Respiratory Illness Associated with Laboratory-Confirmed Pathogens in the Elderly	Results Pending
FBP-001	A phase I/II study of povidone-iodine nasal spray (“Nasodine”) to investigate safety and tolerability in healthy volunteers (Stage 1), and to investigate safety and efficacy in patients with the common cold (Stage 2).	Results Pending
FBP-002	A phase III study of the safety and efficacy of povidone-iodine nasal spray (“Nasodine”) in the treatment of subjects with the common cold in the natural setting.	Results Pending

Protocol Number	Protocol	Results Available?
FLU-AUS-1701	A Prospective Multi-Centre Study of the ellume·lab Flu A+B Test and iTreat Flu A+B Flu Test Performance versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction.	Results Pending
RESP16001	A PROSPECTIVE MULTI-CENTRE STUDY OF THE RESPIRIO FLU TEST AND eLab FLU TEST PERFORMANCE VERSUS REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (RT-PCR) FOR THE RAPID DETECTION OF INFLUENZA A/B.	Results Pending
GAS-AUS-1701	A PROSPECTIVE MULTI-CENTRE STUDY OF THE PERFORMANCE OF THE ELLUME·LAB GROUP A STREP TEST VERSUS CULTURE FOR THE RAPID DETECTION OF GROUP A STREPTOCOCCUS IN PARTICIPANTS WITH ACUTE PHARYNGITIS	Results Pending

Protocol Number	Protocol	Results Available?
RPC01-3202	INDUCTION STUDY #2 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE	Results Pending
GS-US-419-3895	Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease	Results Pending
GS-US-419-3896	A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease	Study Ongoing
GA29144	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE	Study Ongoing
GA29145	AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144	Study Ongoing
GS-US-418-3898	Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis	Results Available
GS-US-418-3899	A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis	Results Available

Protocol Number	Protocol	Results Available?
SHP640-301	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640(PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis	Results Available
SHP640-303	A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640(PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis	Results Available
P2-868963_001	A Multicenter, Prospective, Randomized, Double- Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients with Pterygium	Preliminary Media Release Results Available

Protocol Number	Protocol	Results Available?
1002-043	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT	Preliminary Media Release Results Pending
1245-0167	A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on Exercise ability and heart failure symptoms, In patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF) (EMPERIAL – preserved)	Results Available
1245-0168	A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on Exercise ability and heart failure symptoms, In patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF) (EMPERIAL – reduced)	Preliminary Media Release Results Available
AROAPOC31001	A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as well as in Severely Hypertriglyceridemic Patients and Patients with Familial Chylomicronemia Syndrome	Study Ongoing

Protocol Number	Protocol	Results Available?
BIVV009-03	A PHASE 3 PIVOTAL, OPEN-LABEL,MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION	Results Pending
BIVV009-04	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION	Study Ongoing

Protocol Number	Protocol	Results Available?
V160-002	Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age	Results Pending
FLU009	A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over	Preliminary Media Release Results Available
V199_04	A Phase IIIb-IV, Multicentre, Randomised, Open-label Study to Characterise the Reactogenicity of Afluria Quad Junior in Children 6 Months to Less Than 3 Years, and Afluria Quad in Children 3 Years to Less Than 9 Years Across Three Influenza Seasons	Study Ongoing
2019nCoV-101	A 2-PART, PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A SARS-CoV-2 RECOMBINANT SPIKE PROTEIN NANOPARTICLE VACCINE (SARS-CoV-2 rS) WITH OR WITHOUT MATRIX-M™ ADJUVANT IN HEALTHY SUBJECTS	Recruitment Finished, study ongoing
V201_01	A Phase 2, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Ranging Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine	Results Pending

Protocol Number	Protocol	Results Available?
MT14-AU18GBL208	Phase II, Randomized, Double-Blind, Placebo Controlled, Multi-Center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Glabellar Lines	Study Ongoing
MT14-AU18LCL209	Phase , Randomized, Double-Blind, Placebo Controlled, Multi-Center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Lateral Canthal Lines	Study Ongoing

Protocol Number	Protocol	Results Available?
ZYN2-CL-005	A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multiple Center, Multiple-Dose Study to Assess the Efficacy and Safety of ZYN002 Administered as a Transdermal Gel to Patients with Knee Pain due to Osteoarthritis	Results Pending
Sub-001	A Randomised, Double-blind, Placebo Controlled Study to Investigate the Efficacy on Pain Reduction and Safety of Swisse High Strength Deep Sea Krill Oil (Superba BOOST) in Adults with Mild to Moderate Osteoarthritis of the Knee	Results Pending

Protocol Number	Protocol	Results Available?
ZYN2-CL-03	A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Multiple-Dose Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures, Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy (STAR 1)	Results Pending
ZYN2-CL-004	Open Label Extension Study to ZYN2-CL-03 to Assess the Long Term Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 2)	Results Pending

Protocol Number	Protocol	Results Available?
Nexvax2-1005	A BIOEQUIVALENCE STUDY OF NEXVAX2 IN HLA-DQ2.5+ ADULTS WITH CELIAC DISEASE	Media Release Results Pending
Nexvax2-2006	A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN HLA-DQ2.5+ ADULTS WITH CELIAC DISEASE TO ASSESS THE EFFECT OF NEXVAX2 ON SYMPTOMS AFTER MASKED GLUTEN FOOD CHALLENGE	Study Closure Notification Results Pending
CDX6114-002	A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of CDX-6114 in Patients with Phenylketonuria (PKU).	Study Ongoing

Participate in a Trial | UniSC | University of the Sunshine Coast, Queensland, Australia

Search

Participate in a Trial

Potential new vaccine for preventing chlamydia infection

Select a location

Sunshine Coast and Noosa

Moreton Bay

Brisbane

Specialist cancer trials

Frequently asked questions

Share your experience

Completed studies

Protocol Number	Protocol	Results Available?
ML-004-ER-001	A PHASE 1 OPEN LABEL CROSSOVER STUDY OF ML-004-ER UNDER FASTED AND FED CONDITIONS IN ADULT HEALTHY VOLUNTEERS	Results Pending

Participate in a Trial | UniSC | University of the Sunshine Coast, Queensland, Australia

Accessibility links

Search

Participate in a Trial

Potential new vaccine for preventing chlamydia infection

Select a location

Sunshine Coast and Noosa

Moreton Bay

Brisbane

Specialist cancer trials

Frequently asked questions

Share your experience

Completed studies

Respiratory

Devices

Inflammatory Bowel Diseases

Ophthalmology

Heart & Cardiovascular

Haematology

Vaccines

Cosmetics

Arthritis

Epilepsy

Dietary & Metabolic Intolerances

Neurological